Offshore
Photo
Stock Analysis Compilation
Baron Capital on Tempus $TEM US
Thesis: Tempus AI’s powerful combination of AI-driven diagnostics and an unmatched clinical-genomic data platform positions it to revolutionize personalized medicine and drive significant growth
(Extract from their Q2 letter) https://t.co/S7RAHIspF3
tweet
Baron Capital on Tempus $TEM US
Thesis: Tempus AI’s powerful combination of AI-driven diagnostics and an unmatched clinical-genomic data platform positions it to revolutionize personalized medicine and drive significant growth
(Extract from their Q2 letter) https://t.co/S7RAHIspF3
tweet
Offshore
Photo
Librarian Capital
Nicotine pouches were not historically covered by Tobacco Act in Sweden, being tobacco-free
This was remedied with 2022 Nicotine Act, with restrictions similar to tobacco, incl. on marketing
As in tobacco, municipalities become supervisory bodies for pouches
$HAYPP $PM $BATS https://t.co/rKk5ZhUPmw
tweet
Nicotine pouches were not historically covered by Tobacco Act in Sweden, being tobacco-free
This was remedied with 2022 Nicotine Act, with restrictions similar to tobacco, incl. on marketing
As in tobacco, municipalities become supervisory bodies for pouches
$HAYPP $PM $BATS https://t.co/rKk5ZhUPmw
tweet
Offshore
Photo
Stock Analysis Compilation
Artisan Partners on Vail Resorts $MTN US
Thesis: Vail Resorts’ dominant position, enhanced by advanced pass sales and strategic investments, offers stability and long-term growth potential despite seasonal challenges
(Extract from their Q2 letter) https://t.co/GUfaTo6fcc
tweet
Artisan Partners on Vail Resorts $MTN US
Thesis: Vail Resorts’ dominant position, enhanced by advanced pass sales and strategic investments, offers stability and long-term growth potential despite seasonal challenges
(Extract from their Q2 letter) https://t.co/GUfaTo6fcc
tweet
Offshore
Photo
Librarian Capital
Oral tobacco sales - 2023 sizes for context:
Altria $MO Oral Tobacco: $2,555m
BAT $BATS $BTI: £1,152m (~$1.4bn)
$HAYPP: SEK 521m (~$50m)*
Figures are after excise
$PM doesn't disclose US-only sales, but 2023 SWMA sales were $2,496m, likely ⅔+ from US (incl. cigars) https://t.co/4fxixllObY
tweet
Oral tobacco sales - 2023 sizes for context:
Altria $MO Oral Tobacco: $2,555m
BAT $BATS $BTI: £1,152m (~$1.4bn)
$HAYPP: SEK 521m (~$50m)*
Figures are after excise
$PM doesn't disclose US-only sales, but 2023 SWMA sales were $2,496m, likely ⅔+ from US (incl. cigars) https://t.co/4fxixllObY
tweet
Offshore
Video
Value Spotlight (Andrew Sather)
Animated Guide: Warren Buffett's Thoughts on ROIC, WACC https://t.co/MYyeaVRN1w
tweet
Animated Guide: Warren Buffett's Thoughts on ROIC, WACC https://t.co/MYyeaVRN1w
tweet
Offshore
Photo
Investing visuals
Axon $AXON is one of the fastest growing software companies out there, but not widely discussed.
Here’s the company at a glance👇🔍 https://t.co/afI4suEeRR
tweet
Axon $AXON is one of the fastest growing software companies out there, but not widely discussed.
Here’s the company at a glance👇🔍 https://t.co/afI4suEeRR
tweet
Offshore
Photo
Stock Analysis Compilation
Baron Capital on Alphabet $GOOGL US
Thesis: Alphabet’s AI leadership, coupled with its unmatched scale and financial discipline, offers a compelling risk/reward for long-term investors
(Extract from their Q2 letter) https://t.co/q93tuUV95X
tweet
Baron Capital on Alphabet $GOOGL US
Thesis: Alphabet’s AI leadership, coupled with its unmatched scale and financial discipline, offers a compelling risk/reward for long-term investors
(Extract from their Q2 letter) https://t.co/q93tuUV95X
tweet
AkhenOsiris
@DeItaone is still the 🐐 for breaking news (there's competition though, as Walter's posting frequency has decreased). @MikeZaccardi is hands down the research 🐐 however, good stuff Mike, with the weather reports sprinkled in.
tweet
@DeItaone is still the 🐐 for breaking news (there's competition though, as Walter's posting frequency has decreased). @MikeZaccardi is hands down the research 🐐 however, good stuff Mike, with the weather reports sprinkled in.
tweet
AkhenOsiris
RT @RadnorCapital: Peter Callahan (TMT Sector Specialist at Goldman Sachs) did a nice job summarizing the GenAI state of the union in his Sunday note:
“GenAI check-in … the GenAI theme has certainly become more two sided in recent months with the recent pullback in GenAI Exposed stocks nearly erasing the entire years' outperformance (GS GenAI Basket +14% YTD vs S&P +13%).. While I don't believe the theme has been 'defeated' (as AR/VR or Blockchain or 5G may have been), the theme has become “deflated” as investors worry that the gap between "investment" (capex) to "monetization" (revenue inflections at the app level) is wider than many initially expected (or, investors worry the “costs” are so great that being imaginative enough on the “monetization” side will take some work). Importantly, I get the sense that most investors still believe we eventually make it to point B (tangible productivity gains) -- which leaves me open to the idea that it won’t take much for the theme to get back on track..”
As I’ve said, I think we get to a point where AI capex overshoots, but I don’t think we’re there yet. I continue to believe the companies that “win” this race will accrue massive competitive advantages, which almost makes this spend mission critical. From an economic standpoint, one of the major winners will be the consumer, given the surplus created by new AI use cases / applications.
This is a bit of a tangent, but I say from an “economic standpoint" because advancements in technology generally allow humans to do less, which ultimately results in atrophy. This is a separate, and more philosophical conversation - but the point is, the train has left the station full steam ahead – so the question is how we continue to evolve with these exponential advancements in technology, given humans are linear thinkers.
tweet
RT @RadnorCapital: Peter Callahan (TMT Sector Specialist at Goldman Sachs) did a nice job summarizing the GenAI state of the union in his Sunday note:
“GenAI check-in … the GenAI theme has certainly become more two sided in recent months with the recent pullback in GenAI Exposed stocks nearly erasing the entire years' outperformance (GS GenAI Basket +14% YTD vs S&P +13%).. While I don't believe the theme has been 'defeated' (as AR/VR or Blockchain or 5G may have been), the theme has become “deflated” as investors worry that the gap between "investment" (capex) to "monetization" (revenue inflections at the app level) is wider than many initially expected (or, investors worry the “costs” are so great that being imaginative enough on the “monetization” side will take some work). Importantly, I get the sense that most investors still believe we eventually make it to point B (tangible productivity gains) -- which leaves me open to the idea that it won’t take much for the theme to get back on track..”
As I’ve said, I think we get to a point where AI capex overshoots, but I don’t think we’re there yet. I continue to believe the companies that “win” this race will accrue massive competitive advantages, which almost makes this spend mission critical. From an economic standpoint, one of the major winners will be the consumer, given the surplus created by new AI use cases / applications.
This is a bit of a tangent, but I say from an “economic standpoint" because advancements in technology generally allow humans to do less, which ultimately results in atrophy. This is a separate, and more philosophical conversation - but the point is, the train has left the station full steam ahead – so the question is how we continue to evolve with these exponential advancements in technology, given humans are linear thinkers.
tweet